Skip to content
naulon

Not checkedNot checked for notices yet.

Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report

Tatsuyoshi Ikenoue, Hiroshi Naito, Tetsuya Kitamura and 1 more

Journal of Medical Case Reports · 2017

doi:10.1186/s13256-017-1468-z (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Abstract Background In most patients, anemia is present when myelodysplastic syndrome is diagnosed. Although darbepoetin α is the first-choice supportive therapy for low-risk myelodysplastic syndrome, half of all patients develop a loss of response to darbepoetin α within 12 months. However, few reports have described supportive therapy after the loss of response to darbepoetin α. Case presentation We herein present a case involving a 65-year-old Japanese woman with low-risk myelodysplastic syndrome whose erythropoiesis-stimulating agent treatment was switched from darbepoetin α to epoetin β pegol (continuous erythropoietin receptor activator) to treat transfusion-dependent anemia. The frequent transfusions required to treat the anemia resulted in transfusion-associated circulatory overload. The transfusion-dependent anemia was initially treated with darbepoetin α, which negated the requirement for transfusion. However, after 12 months of darbepoetin α therapy, the hemoglobin concentration sharply declined. We switched her therapy from darbepoetin α to continuous erythropoietin receptor activator to avoid transfusion. After initiation of continuous erythropoietin receptor activator therapy, the hemoglobin concentration gradually increased and transfusion was not required. At the time of writing, no progression of the anemia had occurred. Conclusions Although darbepoetin α is the first-choice supportive therapy for low-risk myelodysplastic syndrome, continuous erythropoietin receptor activator might be considered the second-choice therapy.

Abstract licence: CC BY-NC-ND

References37

    37 more references, whose wording the paper’s licence keeps private.

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.